Oculis Holding AG (NASDAQ:OCS) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Oculis Holding AG (NASDAQ:OCS) have received an average recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $30.17.

Several research firms recently weighed in on OCS. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Oculis in a report on Wednesday, August 28th. Bank of America dropped their price objective on shares of Oculis from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, June 11th. Robert W. Baird boosted their price objective on shares of Oculis from $35.00 to $37.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 11th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of Oculis in a research report on Tuesday, June 11th.

Oculis Trading Down 0.4 %

OCS stock opened at $12.26 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.27 and a quick ratio of 5.27. The company has a market capitalization of $496.58 million, a PE ratio of -6.89 and a beta of 0.30. The firm’s 50-day moving average is $11.85 and its 200 day moving average is $11.84. Oculis has a 12 month low of $9.05 and a 12 month high of $14.47.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Tuesday, August 27th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million during the quarter, compared to the consensus estimate of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. On average, research analysts anticipate that Oculis will post -2.19 EPS for the current year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.